Advances in the Pathogenesis of EBV-Associated Diffuse Large B Cell Lymphoma

Chabay, Paola

doi:10.3390/cancers13112717

Cited by 25 publications

(44 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, little is known about the immunological mechanisms of developing DLBCL during the process of chronic inflammation. 3 To the best of our knowledge, this is the first report of a case of pulmonary EBV-positive DLBCL arising from silicosis examining the underlying immune microenvironment of the silicosis immunohistochemically.…”

Section: Introductionmentioning

confidence: 81%

“…A limitation of this report is that the findings are obtained only in one case. However, EBV‐positive DLBCL has been frequently reported in patients with chronic inflammation, such as pyothorax, metallic implants, chronic skin ulcers, chronic osteomyelitis, and breast implants 3 . The lymphoma cells had a complex karyotype and hypermutated genes 11 .…”

Section: Discussionmentioning

confidence: 99%

“…The lymphoma cells had a complex karyotype and hypermutated genes 11 . In contrast, the lymphoma cells produced immunosuppressive cytokines and downregulated the expression of HLA class I 3 . Unknown factors may be involved in the onset of EBV‐positive DLBCL.…”

Section: Discussionmentioning

confidence: 99%

“…11 In contrast, the lymphoma cells produced immunosuppressive cytokines and downregulated the expression of HLA class I. 3 Unknown factors may be involved in the onset of EBV-positive DLBCL. Further investigations are required to clarify how EBV-positive DLBCL occurs during the process of chronic inflammation.…”

Section: Discussionmentioning

confidence: 99%

“…However, EBV-positive DLBCL has been frequently reported in patients with chronic inflammation, such as pyothorax, metallic implants, chronic skin ulcers, chronic osteomyelitis, and breast implants. 3 The lymphoma cells had a complex karyotype and hypermutated genes. 11 In contrast, the lymphoma cells produced immunosuppressive cytokines and downregulated the expression of HLA class I.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Onset of pulmonary Epstein–Barr virus‐positive diffuse large B‐cell lymphoma in a patient with silicosis

et al. 2021

View full text Add to dashboard Cite

How Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) occasionally occurs following chronic inflammation remains to be elucidated. The case of a 57-year-old man who developed pulmonary EBV-positive DLBCL from underlying silicosis lesions is presented. Immunohistochemical examination of the resected silicosis lesions showed predominant helper T cells and M1/M2 macrophages, with a lack of B cells, regulatory T cells, and resident memory T cells. Two years later, EBVpositive DLBCL emerged unexpectedly from the silicosis. The imbalance of the immune cells in the microenvironment, at least in part, may help explain how chronic inflammation contributes to EBV-positive DLBCL.

show abstract

Section: Introductionmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Onset of pulmonary Epstein–Barr virus‐positive diffuse large B‐cell lymphoma in a patient with silicosis

et al. 2021

View full text Add to dashboard Cite

show abstract

EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk‐stratification, and management

et al. 2022

View full text Add to dashboard Cite

Disease Overview Epstein Barr virus‐positive (EBV+) diffuse large B‐cell lymphoma (DLBCL), not otherwise specified (NOS) is an entity included in the WHO classification of lymphoid neoplasms since 2016. EBV+ DLBCL, NOS, is an aggressive B‐cell lymphoma associated with EBV infection, and a poor prognosis with standard chemotherapeutic approaches. Diagnosis The diagnosis is made through a careful pathological evaluation. Detection of EBV‐encoded RNA (EBER) is considered standard for diagnosis; however, a clear cutoff for percentage of positive cells has not been defined. The differential diagnosis includes plasmablastic lymphoma (PBL), DLBCL associated with chronic inflammation, primary effusion lymphoma (PEL), among others. Risk‐Stratification The International Prognostic Index (IPI) and the Oyama score can be used for risk‐stratification. The Oyama score includes age >70 years and presence of B symptoms. The expression of CD30 and PD‐1/PD‐L1 are emerging as potential adverse but targetable biomarkers. Management Patients with EBV+ DLBCL, NOS, should be staged and managed following similar guidelines than patients with EBV‐negative DLBCL. EBV+ DLBCL, NOS, however, might have a worse prognosis than EBV‐negative DLBCL in the era of chemoimmunotherapy. Therefore, the inclusion of patients in clinical trials when available is recommended. There is an opportunity to study and develop targeted therapy in the management of patients with EBV+ DLBCL, NOS.

show abstract

Global patterns of non‐Hodgkin lymphoma in 2020

Costa

Laversanne

Gospodarowicz

et al. 2022

Intl Journal of Cancer

View full text Add to dashboard Cite

We evaluated the global patterns of non-Hodgkin lymphoma (NHL) in 2020 using the estimates of NHL incidence and mortality in 185 countries that are part of the GLO-BOCAN 2020 database, developed by the International Agency for Research on Cancer (IARC). As well as new cases and deaths of NHL, corresponding age-standardized (world) rates (ASR) of incidence and mortality per 100 000 person-years were derived by country and world region. In 2020, an estimated 544 000 new cases of NHL were diagnosed worldwide, and approximately 260 000 people died from the disease. Eastern Asia accounted for a quarter (24.9%) of all cases, followed by Northern America (15.1%) and South-Central Asia (9.7%). Incidence rates were higher in men than in women, with similar geographical patterns. While the incidence rates were highest in Australia and New Zealand, Northern America, Northern Europe and Western Europe (>10/100 000 for both sexes combined), the highest mortality rates (>3/100 000) were found in regions in Africa, Western Asia and Oceania. The large variations and the disproportionately higher mortality in low-and middle-income countries can be related to the underlying prevalence and distribution of risk factors, and to the level of access to diagnostic and treatment facilities.

show abstract

Advances in the Pathogenesis of EBV-Associated Diffuse Large B Cell Lymphoma

Cited by 25 publications

References 109 publications

Onset of pulmonary Epstein–Barr virus‐positive diffuse large B‐cell lymphoma in a patient with silicosis

Onset of pulmonary Epstein–Barr virus‐positive diffuse large B‐cell lymphoma in a patient with silicosis

EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk‐stratification, and management

Global patterns of non‐Hodgkin lymphoma in 2020

Contact Info

Product

Resources

About